PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis-Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis-Global Drug Forecast and Market Analysis to 2025


  • Products Id :- GDHC137PIDR
  • |
  • Pages: 407
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis-Global Drug Forecast and Market Analysis to 2025

Summary

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. As a multisystem disorder, SLE is heterogeneous in nature-no two cases of lupus are alike-and can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The etiology of SLE and LN remains incompletely understood, but genetic and environmental factors have been shown to play pivotal roles in the development of the disease.

To date, the cornerstone of lupus therapy still relies on generic steroids and unspecific immunosuppressive agents; both of which are associated with severe adverse events (SAEs) and contribute significantly to the morbidity and mortality in lupus. The much anticipated approval of Benlysta (belimumab) in 2011 had only a small impact on the treatment paradigm, and off-label Rituxan/MabThera (rituximab) remains the market leader in terms of sales. R&D efforts in lupus are high, however late-stage clinical failure remains a major barrier to market entry. The anticipated release of six new pipeline agents for SLE and LN will have the potential to revolutionize the lupus treatment. GlobalData expects the global SLE and LN market-which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan)-to expand during the next decade at an astonishing CAGR of 10.6%, reaching total sales of $3.2 billion by 2025.

Highlights

Key Questions Answered

Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the SLE and LN marketplace.

What will be the effect of recent and upcoming biologics on the SLE and LN treatment landscape?

How will the upcoming first-in-class and me-too pipeline agents be received in the different markets?

What research and development (R&D) strategies will companies leverage to compete in the future SLE and LN marketplace?

Which patient population(s) are most likely to be targeted by newly introduced pipeline agents?

Key Findings

GlobalData has calculated that the global SLE and LN market generated about $1.2 billion in sales in 2015. This global market is expected to grow by an astonishingly strong compound annual growth rate (CAGR) of 10.6% from 2015-2025, reaching annual sales of $3.2 billion by the end of the forecast period. The majority of this growth will occur in the US, driven by an increased diagnosed disease prevalence of SLE and LN and the launch of three new first-in-class pipeline drugs (anifrolumab, Orencia [abatacept], and Lupuzor) and three improved therapeutic options (atacicept, blisibimod, and voclosporin). The SLE and LN market in the US is expected to grow at a CAGR of 10.4%, reaching sales of $2.8 billion by 2025. GlobalData estimates that sales in the 5EU to grow at a CAGR of 14.1% during the next 10 years, reaching $312.4m by 2025, while Japan will experience the lowest growth with a CAGR of 9.8%.

KOLs interviewed by GlobalData repeatedly identified the need for efficacious drugs as the most important clinical unmet need, with reducing lupus morbidity and mortality and the development of sensitive and reliable biomarkers for diagnosis and disease management as key areas of need as well.

GlobalData anticipates that opportunities will center on the development of safer and more efficacious drugs to treat the various disease manifestations in lupus.

Scope

Overview of SLE and LN, including epidemiology, etiology, pathophysiology, as well current routine SLE and LN recommendations of all 7MM covered.

Top-line SLE and LN market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the SLE and LN market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global SLE and LN marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to-

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global SLE and LN market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SLE and LN market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 10

1.1 List of Tables 17

1.2 List of Figures 22

2 Introduction 24

2.1 Catalyst 24

2.2 Related Reports 25

2.3 Upcoming Related Reports 25

3 Disease Overview 26

3.1 Etiology and Pathophysiology 26

3.1.1 Etiology 26

3.1.2 Pathophysiology 27

3.2 Symptoms 29

3.3 Prognosis 31

3.4 Quality of Life 32

4 Epidemiology 33

4.1 Disease Background 33

4.2 Risk Factors and Comorbidities 35

4.3 Global Trends 37

4.3.1 SLE and LN Prevalence 37

4.3.2 LN Classification 41

4.4 Forecast Methodology 41

4.4.1 Sources Used 42

4.4.2 Forecast Assumptions and Methods 47

4.4.3 Sources Not Used 59

4.5 Epidemiological Forecast for SLE and LN (2015-2025) 61

4.5.1 Diagnosed Prevalent Cases of SLE 61

4.5.2 Age-Specific Diagnosed Prevalent Cases of SLE 63

4.5.3 Sex-Specific Diagnosed Prevalent Cases of SLE 65

4.5.4 Age-Standardized Diagnosed Prevalence of SLE 67

4.5.5 Diagnosed Prevalent Cases of SLE Segmented by Severity 68

4.5.6 Diagnosed Prevalent Cases of LN 70

4.5.7 Diagnosed Prevalent Cases of LN Segmented by Class 72

4.6 Discussion 76

4.6.1 Epidemiological Forecast Insight 76

4.6.2 Limitations of the Analysis 77

4.6.3 Strengths of the Analysis 79

5 Disease Management 80

5.1 Diagnosis Overview 80

5.1.1 SLE Diagnosis 80

5.1.2 LN Diagnosis 83

5.2 Treatment Overview 85

5.2.1 Treatment Guidelines and Leading Prescribed Drugs 87

5.3 US 90

5.3.1 Diagnosis 91

5.3.2 Clinical Practice 92

5.4 France 94

5.4.1 Diagnosis 95

5.4.2 Clinical Practice 95

5.5 Germany 97

5.5.1 Diagnosis 98

5.5.2 Clinical Practice 98

5.6 Italy 100

5.6.1 Diagnosis 101

5.6.2 Clinical Practice 101

5.7 Spain 103

5.7.1 Diagnosis 104

5.7.2 Clinical Practice 104

5.8 UK 106

5.8.1 Diagnosis 107

5.8.2 Clinical Practice 107

5.9 Japan 109

5.9.1 Diagnosis 110

5.9.2 Clinical Practice 110

6 Competitive Assessment 112

6.1 Overview 112

6.2 Strategic Competitor Assessment 113

6.3 Product Profiles-Major Brands, Small Molecules 114

6.3.1 Antimalarials (numerous brand names) 114

6.3.2 Steroids (numerous brand names) 122

6.3.3 Methotrexate (numerous brand names) 129

6.3.4 Mycophenolate Mofetil (numerous brand names) 136

6.3.5 Cyclophosphamide (numerous brand names) 145

6.3.6 Azathioprine (numerous brand names) 151

6.3.7 Calcineurin Inhibitors (numerous brand names) 158

6.4 Product Profiles-Major Brands, Biologics 167

6.4.1 Benlysta (belimumab) 167

6.4.2 Rituxan (rituximab) 177

6.5 Minor Therapeutic Classes 185

7 Unmet Needs Assessment and Opportunity Analysis 186

7.1 Overview 186

7.2 Drugs with Superior Efficacy and Safety Profiles, Particularly for LN 188

7.2.1 Unmet Need 188

7.2.2 Gap Analysis 192

7.2.3 Opportunity 195

7.3 Refined Clinical Trial Design Tailored to Heterogeneous Lupus Patient Populations 197

7.3.1 Unmet Need 197

7.3.2 Gap Analysis 198

7.3.3 Opportunity 200

7.4 Reduced Morbidity and Mortality in Lupus Patients 203

7.4.1 Unmet Need 203

7.4.2 Gap Analysis 204

7.4.3 Opportunity 205

7.5 Improved Physician Education 207

7.5.1 Unmet Need 207

7.5.2 Gap Analysis 208

7.5.3 Opportunity 210

7.6 Sensitive and Reliable Biomarkers for Diagnosis and Disease Management 211

7.6.1 Unmet Need 211

7.6.2 Gap Analysis 212

7.6.3 Opportunity 213

7.7 Increased Compliance Rates for SOC SLE and LN Therapies 213

7.7.1 Unmet Need 213

7.7.2 Gap Analysis 214

7.7.3 Opportunity 215

8 Pipeline Assessment 216

8.1 Overview 216

8.2 Clinical Trial Mapping 216

8.2.1 Clinical Trials by Therapy Type 216

8.3 Promising Drugs in Late-Stage Clinical Development 217

8.3.1 Blisibimod 221

8.3.2 Atacicept 231

8.3.3 Orencia (abatacept) 239

8.3.4 Anifrolumab 247

8.3.5 Lupuzor (IPP-201101, P-140) 255

8.3.6 Voclosporin 261

8.4 Promising Drugs in Early-Stage Clinical Development 270

8.4.1 Overview 270

8.5 Other Drugs in Clinical Development 278

8.6 Biosimilars 280

8.6.1 Overview 280

8.6.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases 281

8.6.3 Biosimilars in the Immunology Community 281

8.6.4 By the Numbers: Biosimilars in Development for Potential Off-Label Use in SLE and LN 281

8.6.5 The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry 284

8.6.6 Uptake of Biosimilars for SLE and LN Is Expected to Vary by Country/Region 285

8.6.7 Biosimilars Forecast for SLE and LN 285

9 Current and Future Players 287

9.1 Overview 287

9.2 Trends in Corporate Strategy 291

9.3 Company Profiles 292

9.3.1 GlaxoSmithKline 292

9.3.2 Roche 294

9.3.3 Bristol-Myers Squibb 296

9.3.4 AstraZeneca 298

9.3.5 Merck KGaA 300

9.3.6 Anthera Pharmaceuticals 302

9.3.7 Aurinia Pharmaceuticals 303

9.3.8 ImmuPharma 305

9.3.9 Pfizer 306

10 Market Outlook 307

10.1 Global Markets 307

10.1.1 Forecast 307

10.1.2 Drivers and Barriers-Global Issues 316

10.2 US 317

10.2.1 Forecast 317

10.2.2 Key Events 321

10.2.3 Drivers and Barriers 322

10.3 5EU 322

10.3.1 Forecast 322

10.3.2 Key Events 329

10.3.3 Drivers and Barriers 330

10.4 Japan 330

10.4.1 Forecast 330

10.4.2 Key Events 335

10.4.3 Drivers and Barriers 336

11 Appendix 337

11.1 Bibliography 337

11.2 Abbreviations 371

11.3 Methodology 376

11.4 Forecasting Methodology 376

11.4.1 Diagnosed SLE and LN Patients 376

11.4.2 Drugs Included in Each Therapeutic Class 377

11.4.3 Percent Drug-Treated Patients 378

11.4.4 Launch and Patent Expiry Dates 379

11.4.5 General Pricing Assumptions 381

11.4.6 Individual Drug Assumptions 382

11.4.7 Generic Erosion 394

11.4.8 Pricing of Pipeline Agents 395

11.5 Primary Research-KOLs Interviewed for this Report 397

11.6 Primary Research-Prescriber Survey 401

11.7 About the Authors 402

11.7.1 Analyst 402

11.7.2 Therapy Area Directors 402

11.7.3 Epidemiologists 403

11.7.4 Global Director of Therapy Analysis and Epidemiology 405

11.8 About GlobalData 406

11.9 Disclaimer 406

1.1 List of Tables

Table 1: Symptoms of SLE 30

Table 2: The 1982 Revised ACR Criteria For Classification of Systemic Lupus Erythematosus 34

Table 3: WHO and ISN/RPS Classification Systems for LN 35

Table 4: Risk Factors for SLE 36

Table 5: 7MM, Sources Used for Diagnosed Prevalence of SLE 43

Table 6: 7MM, Sources Used for Diagnosed Prevalence of Mild and Moderate/Severe SLE 44

Table 7: 7MM, Sources Used for Diagnosed Prevalence of LN 45

Table 8: 7MM, Sources Used for Diagnosed Prevalent Cases of LN Classified by the WHO Classification 46

Table 9: 7MM, Sources Used for Classifying LN by the ISN/RPS Classification 47

Table 10: 7MM, Sources Not Used in Epidemiological Analysis of SLE 60

Table 11: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, Select Years 2015-2025 62

Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of SLE, Both Sexes, N, Row (%), 2015 64

Table 13: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, Row (%), 2015 66

Table 14: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, Row (%), 2015 69

Table 15: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, Select Years 2015-2025 71

Table 16: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, Row (%), 2015 72

Table 17: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, Row (%), 2015 74

Table 18: Updated (1997) ACR Criteria for Classification of SLE 81

Table 19: The SLICC Clinical and Immunologic Criteria for Classification of SLE 82

Table 20: WHO and ISN/RPS Classifications of LN 84

Table 21: Treatment Guidelines for SLE and LN 88

Table 22: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2015 89

Table 23: Country Profile-US 90

Table 24: Country Profile-France 94

Table 25: Country Profile-Germany 97

Table 26: Country Profile-Italy 100

Table 27: Country Profile-Spain 103

Table 28: Country Profile-UK 106

Table 29: Country Profile-Japan 109

Table 30: Leading Treatments for SLE and LN, 2016 114

Table 31: Product Profile-Hydroxychloroquine 116

Table 32: Efficacy of Antimalarial Therapy in Lupus 117

Table 33: Safety of Antimalarial Therapy in Lupus 119

Table 34: Antimalarial Therapy SWOT Analysis, 2016 120

Table 35: Global Sales Forecasts ($m) of Antimalarials* for SLE and LN Therapy, 2015-2025 122

Table 36: Product Profile-Steroids 125

Table 37: Efficacy of Steroids in SLE Patients 126

Table 38: Safety of Long-Term Prednisone Use* 127

Table 39: Steroids SWOT Analysis, 2016 128

Table 40: Global Sales Forecasts ($m) of Steroids* for SLE and LN Therapy, 2015-2025 129

Table 41: Product Profile-Methotrexate 131

Table 42: Steroid-Sparing Effect of Methotrexate 133

Table 43: Safety of Methotrexate 134

Table 44: Methotrexate SWOT Analysis, 2016 135

Table 45: Global Sales Forecasts ($m) of Methotrexate* for SLE and LN Therapy, 2015-2025 136

Table 46: Product Profile-Mycophenolate Mofetil 138

Table 47: Efficacy of Mycophenolate Mofetil 140

Table 48: Safety of Mycophenolate Mofetil 142

Table 49: Mycophenolate Mofetil SWOT Analysis, 2016 143

Table 50: Global Sales Forecasts ($m) of Mycophenolate Mofetil for SLE and LN Therapy, 2015-2025 144

Table 51: Product Profile-Cyclophosphamide 146

Table 52: Efficacy of Cyclophosphamide 147

Table 53: Safety of Cyclophosphamide 149

Table 54: Cyclophosphamide SWOT Analysis, 2016 150

Table 55: Global Sales Forecasts ($m) of Cyclophosphamide* for SLE and LN Therapy, 2015-2025 151

Table 56: Product Profile-Azathioprine 153

Table 57: Efficacy of Azathioprine 155

Table 58: Safety of Azathioprine 156

Table 59: Azathioprine SWOT Analysis, 2016 157

Table 60: Global Sales Forecasts ($m) of Azathioprine* for SLE and LN Therapy, 2015-2025 158

Table 61: Product Profile-Calcineurin Inhibitors 160

Table 62: Efficacy of Calcineurin Inhibitors 162

Table 63: Safety of Calcineurin Inhibitors 164

Table 64: Calcineurin Inhibitors SWOT Analysis, 2016 165

Table 65: Global Sales Forecasts ($m) of Calcineurin Inhibitors* for SLE and LN Therapy, 2015-2025 166

Table 66: Product Profile-Benlysta 169

Table 67: Efficacy of Benlysta 171

Table 68: Safety of Benlysta 174

Table 69: Benlysta SWOT Analysis, 2016 175

Table 70: Global Sales Forecasts ($m) of Benlysta for SLE and LN Therapy, 2015-2025 177

Table 71: Product Profile-Rituxan 179

Table 72: Efficacy of Rituxan 181

Table 73: Safety of Rituxan 182

Table 74: Rituxan SWOT Analysis, 2016 183

Table 75: Global Sales Forecasts ($m) of Rituxan for SLE and LN Therapy, 2015-2025 184

Table 76: Summary of Minor Therapeutic Classes for the Treatment of SLE and LN, 2016 185

Table 77: Unmet Need and Opportunity in SLE and LN, 2016 187

Table 78: Key Late-Stage Pipeline Agents for SLE and LN, 2016 218

Table 79: Product Profile-Blisibimod 223

Table 80: Blisibimod SWOT Analysis, 2016 229

Table 81: Global Sales Forecasts (7MM) for Blisibimod in SLE and LN, 2015-2025 230

Table 82: Product Profile-Atacicept 233

Table 83: Atacicept SWOT Analysis, 2016 237

Table 84: Global Sales Forecasts ($m) for Atacicept in SLE and LN, 2015-2025 239

Table 85: Product Profile-Orencia 241

Table 86: Orencia SWOT Analysis, 2016 245

Table 87: Global Sales Forecasts ($m) for Orencia in SLE and LN, 2015-2025 246

Table 88: AstraZeneca's Anifrolumab-Key Phase II and Phase III Clinical Trials 248

Table 89: Product Profile-Anifrolumab 249

Table 90: Anifrolumab SWOT Analysis, 2016 253

Table 91: Global Sales Forecasts ($m) for Anifrolumab in SLE and LN, 2015-2025 254

Table 92: Product Profile-Lupuzor 256

Table 93: Lupuzor SWOT Analysis, 2016 260

Table 94: Global Sales Forecasts ($m) for Lupuzor in SLE and LN, 2015-2025 261

Table 95: Product Profile-Voclosporin 263

Table 96: Voclosporin SWOT Analysis, 2016 268

Table 97: Global Sales Forecasts ($m) for Voclosporin in SLE and LN, 2015-2025 269

Table 98: Other Promising Clinical-Stage Drugs in Development for SLE/LN, 2016 270

Table 99: Drugs in Development for SLE and LN, 2016 279

Table 100: Biosimilars Pipeline for RA, 2016 283

Table 101: Global Sales Forecasts ($m) for Biosimilars (Rituximab and Abatacept) in SLE and LN, 2015-2025 286

Table 102: Key Companies in the SLE and LN Market in the 7MM, 2016 289

Table 103: GSK's SLE and LN Portfolio Assessment, 2016 294

Table 104: Roche's SLE and LN Portfolio Assessment, 2016 296

Table 105: BMS' SLE and LN Portfolio Assessment, 2016 298

Table 106: AstraZeneca's SLE and LN Portfolio Assessment, 2016 300

Table 107: Merck KGaA's SLE and LN Portfolio Assessment, 2016 301

Table 108: Anthera's SLE and LN Portfolio Assessment, 2016 303

Table 109: Aurinia's SLE and LN Portfolio Assessment, 2016 304

Table 110: ImmuPharma's SLE and LN Portfolio Assessment, 2016 306

Table 111: Pfizer's SLE and LN Portfolio Assessment, 2016 306

Table 112: Global (7MM) Sales Forecasts ($m) for SLE and LN, 2015-2025 312

Table 113: SLE and LN Market-Global Drivers and Barriers, 2015?2025 316

Table 114: Sales Forecasts ($m) for SLE and LN in the US, 2015-2025 319

Table 115: Key Events Impacting Sales for SLE and LN in the US, 2015-2025 321

Table 116: SLE and LN Market-Drivers and Barriers in the US, 2015?2025 322

Table 117: Sales Forecasts ($m) for SLE and LN in the 5EU, 2015-2025 325

Table 118: Key Events Impacting Sales for SLE and LN in the 5EU, 2015-2025 329

Table 119: SLE and LN Market-Drivers and Barriers in the 5EU, 2015?2025 330

Table 120: Sales Forecasts ($m) for SLE and LN in Japan, 2015-2025 333

Table 121: Key Events Impacting Sales for SLE and LN in Japan, 2015-2025 335

Table 122: SLE and LN Market-Drivers and Barriers in Japan, 2015?2025 336

Table 123: Key Historical and Projected Launch Dates for SLE and LN 379

Table 124: Key Historical and Projected Patent Expiry Dates for SLE and LN 380

Table 125: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 401

1.2 List of Figures

Figure 1: Overview of the Etiology and Pathogenesis of SLE 27

Figure 2: Integrated Hypothesis for the Pathogenesis of SLE 29

Figure 3: SLE Forecast Case Flow Map 42

Figure 4: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, 2015-2025 62

Figure 5: 7MM, Diagnosed Prevalent Cases of SLE, by Age, Both Sexes, N, 2015 65

Figure 6: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, 2015 67

Figure 7: 7MM, Age-Standardized Diagnosed Prevalence (Cases per 100,000 Population) of SLE, All Ages, by Sex, 2015 68

Figure 8: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, 2015 70

Figure 9: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, 2015?2025 71

Figure 10: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, 2015 73

Figure 11: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, 2015 75

Figure 12: Overview of the Treatment Management of SLE and LN 85

Figure 13: SLE and LN Therapeutics-Clinical Trials by Type of Therapy and Development Stage, December 2016 217

Figure 14: SLE and LN-Key Phase II?III Clinical Trials, 2016 219

Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2015-2025 221

Figure 16: Company Portfolio Gap Analysis in SLE and LN, 2015-2025 290

Figure 17: Average Annual Cost of Therapy (ACOT) for SLE and LN, 2016 311

Figure 18: Global (7MM) Sales for SLE and LN by Country/Region, 2015 and 2025 313

Figure 19: Global (7MM) Sales for SLE and LN by Region, 2015?2025 314

Figure 20: Global (7MM) Sales for SLE and LN by Drug, 2015 and 2025 315

Figure 21: Sales for SLE and LN by Drug Class in the US, 2015 320

Figure 22: Sales for SLE and LN by Drug Class in the 5EU, 2015 and 2025 326

Figure 23: Global Sales for SLE and LN by Country in the 5EU, 2015 and 2025 327

Figure 24: Global Sales for SLE and LN by Country in the 5EU, 2015?2025 328

Figure 25: Sales for SLE and LN by Drug Class in Japan, 2015 and 2025 334

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

GlaxoSmithKline, Roche, Bristol-Myers Squibb, AstraZeneca, Merck KGaA, Anthera Pharmaceuticals, Aurinia Pharmaceuticals, ImmuPharma, Pfizer

select a license
Single User License
USD 10995 INR 784823
Site License
USD 21990 INR 1569646
Corporate User License
USD 32985 INR 2354469

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com